<DOC>
	<DOCNO>NCT02981498</DOCNO>
	<brief_summary>To evaluate safety efficacy combine hepatic arterial infusion ( HAIC ) oxaliplatin , 5-fluorouracil leucovorin sorafenib patient advance hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Phase II Trial Sorafenib Combined With Concurrent HAIC Hepatocellular Carcinoma</brief_title>
	<detailed_description>In current guideline , unresectable HCC major PVTT consider generally suitable transarterial chemoembolization , sorafenib recommend standard care.3-5 However , patient major PVTT , median overall survival treat sorafenib monotherapy 3.1 6.0 month . Whether combine sorafenib hepatic arterial infusion ( HAIC ) oxaliplatin , 5-fluorouracil leucovorin safe , well tolerate , efficacious remains unknown , prospective clinical data currently available.The investigator therefore conduct prospective single center , single-arm phase II trial evaluate safety efficacy sorafenib combine HAIC patient unresectable advanced HCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Criteria : The diagnosis HCC base diagnostic criterion HCC use European Association Study Liver ( EASL ) Patients must least one tumor lesion accurately measure accord EASL criterion . diagnosed major main portal vein invasion ( Vp3 Vp4 ) KPS≥70； previous treatment No Cirrhosis cirrhotic status ChildPugh class A Not amendable surgical resection , local ablative therapy cure treatment . The following laboratory parameter : Platelet count ≥ 75,000/µL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 30 g/L ASL AST ≤ 5 x upper limit normal Serum creatinine ≤ 1.5 x upper limit normal INR ≤ 1.5 PT/APTT within normal limit Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Ability understand protocol agree sign write informed consent document Evidence hepatic decompensation include ascites , gastrointestinal bleeding hepatic encephalopathy Known history HIV History organ allograft Known suspect allergy investigational agent agent give association trial . Cardiac ventricular arrhythmia require antiarrhythmic therapy Evidence bleeding diathesis . Patients clinically significant gastrointestinal bleeding within 30 day prior study entry . Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug Serious nonhealing wound , ulcer , bone fracture Known central nervous system tumor include metastatic brain disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatic arterial infusion chemotherapy</keyword>
	<keyword>Sorafenib</keyword>
</DOC>